Causes of death in a cohort treated for opioid dependence between 1985 and 2005.

AIMS To examine changes in causes of death in a cohort treated for opioid dependence, across time and age; quantify years of potential life lost (YPLL); and identify avoidable causes of death. DESIGN People in New South Wales (NSW) who registered for opioid substitution therapy (OST), 1985-2005, were linked to a register of all deaths in Australia. SETTING NSW, Australia. MEASUREMENTS Crude mortality rates (CMRs), age-sex-standardized mortality rates (ASSRs) and standardized mortality ratios (SMRs) across time, sex and age. Years of potential life lost (YPLL) were calculated with reference to Australian life tables and by calculating years lost before the age of 65 years. FINDINGS There were 43 789 people in the cohort, with 412 216 person-years of follow-up. The proportion of the cohort aged 40+ years increased from 1% in 1985 to 39% in 2005. Accidental opioid overdoses, suicides, transport accidents and violent deaths declined with age; deaths from cardiovascular disease, liver disease and cancer increased. Among men, 89% of deaths were potentially avoidable; among women, 86% of deaths were avoidable. There were an estimated 160 555 YPLL in the cohort, an average of 44 YPLL per decedent and an average of 29 YPLL before age 65 years. CONCLUSIONS Among a cohort of opioid-dependent people in New South Wales, 1985-2005, almost nine in 10 deaths in the cohort were avoidable. There is huge scope to improve mortality among opioid-dependent people.

[1]  Matt Anderson,et al.  European Monitoring Centre for Drugs and Drug Addiction , 2014 .

[2]  R. Mattick,et al.  Imprisonment of opioid‐dependent people in New South Wales, Australia, 2000–2012: a retrospective linkage study , 2014, Australian and New Zealand journal of public health.

[3]  D. Randall,et al.  The contributions of viral hepatitis and alcohol to liver-related deaths in opioid-dependent people. , 2013, Drug and alcohol dependence.

[4]  D. Randall,et al.  The increasing mortality burden of liver disease among opioid-dependent people: cohort study. , 2011, Addiction.

[5]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[6]  M. Law,et al.  Increasing cancer mortality among opioid‐dependent persons in Australia: a new public health challenge for a disadvantaged population , 2011, Australian and New Zealand Journal of Public Health.

[7]  Rosie P Cornish,et al.  Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database , 2010, BMJ : British Medical Journal.

[8]  M. Farrell,et al.  Meta-analysis of drug-related deaths soon after release from prison , 2010, Addiction.

[9]  T. Rhodes,et al.  Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed , 2010, The Lancet.

[10]  G. Stimson,et al.  Illegal drug use in the age of ageing. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[11]  Matthew Hickman,et al.  HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage , 2010, The Lancet.

[12]  W. Hall,et al.  Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. , 2009, Drug and alcohol dependence.

[13]  S. Lenton,et al.  Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia. , 2009, Drug and alcohol review.

[14]  S. Lenton,et al.  Naloxone for administration by peers in cases of heroin overdose , 2009, The Medical journal of Australia.

[15]  Louisa Degenhardt,et al.  Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. , 2009, Addiction.

[16]  Matthew Hickman,et al.  Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review , 2008, The Lancet.

[17]  D. Jolley,et al.  Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). , 2008, Drug and alcohol dependence.

[18]  C. Reynolds,et al.  The prevalence of mental and physical health disorders among older methadone patients. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[19]  R. Pavarin.  [Mortality risk in intravenous drug users in Bologna and its determining factors. Results of a longitudinal study]. , 2008, Epidemiologia e prevenzione.

[20]  Y. Hser,et al.  Years of potential life lost among heroin addicts 33 years after treatment. , 2007, Preventive medicine.

[21]  Raimondo Bruno,et al.  Australian Drug Trends 2004: Findings from the Illicit Drug Reporting System (IDRS) , 2006 .

[22]  L. Degenhardt,et al.  Changes in the initiation of heroin use after a reduction in heroin supply. , 2006, Drug and alcohol review.

[23]  L. Degenhardt,et al.  Documenting the heroin shortage in New South Wales. , 2006, Drug and alcohol review.

[24]  R. Manfredi,et al.  Trend of mortality observed in a cohort of drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a 25-year-period. , 2006, Collegium antropologicum.

[25]  M. Davoli,et al.  Drug-related mortality and its impact on adult mortality in eight European countries. , 2006, European journal of public health.

[26]  L. Degenhardt,et al.  Recent trends in heroin supply to markets in Australia, the United States and Western Europe , 2005 .

[27]  L. Degenhardt,et al.  The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia , 2005, BMC public health.

[28]  W. Hall,et al.  Being realistic about benefits of supervised injecting facilities , 2005, The Lancet.

[29]  M. Brugal,et al.  Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. , 2005, Addiction.

[30]  L. Degenhardt,et al.  Effects of a sustained heroin shortage in three Australian States. , 2005, Addiction.

[31]  W. Hall,et al.  The effect of a reduction in heroin supply on fatal and non‐fatal drug overdoses in New South Wales, Australia , 2005, The Medical journal of Australia.

[32]  W. McCarthy,et al.  Health Conditions Among Aging Narcotics Addicts: Medical Examination Results , 2004, Journal of Behavioral Medicine.

[33]  L. Degenhardt,et al.  Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes , 2004, BMJ : British Medical Journal.

[34]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[35]  S. Galea,et al.  Characteristics of drug users who witness many overdoses: implications for overdose prevention. , 2012, Drug and alcohol dependence.

[36]  L. Degenhardt,et al.  Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. , 2011, Addiction.

[37]  L. Degenhardt,et al.  Sex differences amongst dependent heroin users: histories, clinical characteristics and predictors of other substance dependence. , 2011, Addictive behaviors.

[38]  J. Glover,et al.  Australian and New Zealand Atlas of Avoidable Mortality , 2006 .

[39]  W. Hall,et al.  The Illicit Drug Reporting System (IDRS) 1996-2000 , 2000 .

[40]  Louisa J Degenhardt,et al.  The "lessons" of the Australian "heroin shortage" , 2006, Substance abuse treatment, prevention, and policy.